Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and
progesterone receptor expression and lacks HER2 overexpression or gene amplification. It …

Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the
highest rates of recurrence and mortality. The lack of expression of targetable proteins such …

Global estimates indicated 2.3 million new cases of breast cancer in 2020, contributing to
nearly 12% of all new cancer cases, with 685 000 deaths in the same year. 1 Breast cancer …

Breast cancer is treated with a multidisciplinary approach involving surgical oncology,
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …

Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Background Trastuzumab targets the extracellular domain of the HER2 protein. Adding
trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer …

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …

Abstract Background The 16th St. Gallen International Breast Cancer Conference 2019 in
Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies …

With nearly 10 million deaths, cancer is the leading cause of mortality worldwide. Along with
major key parameters that control cancer treatment management, such as diagnosis …

Background Anthracycline–taxane chemotherapy for early-stage breast cancer substantially
improves survival compared with no chemotherapy. However, concerns about short-term …